Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MediWound Ltd. - Ordinary Shares (NQ:MDWD)

16.70 -0.12 (-0.71%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about MediWound Ltd. - Ordinary Shares

< Previous 1 2 3 4 5 6 Next >
MediWound Announces Phase II Head-to-Head Study Evaluating EscharEx® vs. Collagenase in Patients with Venous Leg Ulcers
From MediWound Ltd.
Via GlobeNewswire
MediWound to Participate in the 2024 Maxim Healthcare Virtual Summit
From MediWound Ltd.
Via GlobeNewswire
MediWound to Present at the H.C. Wainwright 26th Annual Global Investment Conference
From MediWound Ltd.
Via GlobeNewswire
MediWound Announces U.S. Food and Drug Administration Approval of NexoBrid® for the Treatment of Pediatric Patients with Severe Thermal Burns
Approval Helps Solidify NexoBrid’s Position in the U.S. as a Safe and Effective Non-Surgical Burn Treatment for All Ages 
From MediWound Ltd.
Via GlobeNewswire
Preview: MediWound's Earnings
 
Via Benzinga
MDWD Stock Earnings: MediWound Misses EPS, Beats Revenue for Q2 2024
MDWD stock results show that MediWound missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
Via InvestorPlace
MediWound Reports Second Quarter 2024 Financial Results and Provides Company Update
From MediWound Ltd.
Via GlobeNewswire
MediWound Announces Positive Results from the U.S. NexoBrid® Expanded Access Protocol (NEXT)
NEXT Confirms NexoBrid's Proven Safety and Efficacy in Eschar Removal, Significantly Reducing Surgical Procedures for Burn Patients 
From MediWound Ltd.
Via GlobeNewswire
MediWound to Report Second Quarter 2024 Financial Results
Conference Call and Webcast Scheduled for Wednesday, August 14th at 8:30 am Eastern Time 
From MediWound Ltd.
Via GlobeNewswire
MediWound Announces Publication of the EscharEx® Phase II ChronEx Study Results for Venous Leg Ulcers
From MediWound Ltd.
Via GlobeNewswire
MediWound Announces €16.25 Million Funding from the European Innovation Council Accelerator Program
From MediWound Ltd.
Via GlobeNewswire
MediWound Announces $25 Million Strategic Private Placement Financing
Mölnlycke Health Care, a global leader in innovative wound care solutions, leads the PIPE with a $15 million investment 
From MediWound Ltd.
Via GlobeNewswire
Why NIO Shares Are Trading Lower By Over 8%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of NIO Inc. (NYSE:NIO) fell sharply during Friday's session after the company disclosed that Steven Wei Feng has resigned as the Chief Financial Officer for personal and family 
Via Benzinga
US Stocks Mixed; Jobs Figures Top Estimates For June
 
Via Benzinga
Why Sharps Technology Shares Are Trading Higher By Around 32%; Here Are 20 Stocks Moving Premarket
Shares of Sharps Technology, Inc. (NASDAQ:STSS) rose sharply in today's pre-market trading after the company announced it received two purchase orders for a total of approximately one million... 
Via Benzinga
MDWD Stock Earnings: MediWound Beats EPS, Beats Revenue for Q1 2024
MDWD stock results show that MediWound beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
MediWound Reports First Quarter 2024 Financial Results and Provides Company Update
From MediWound Ltd.
Via GlobeNewswire
MediWound to Report First Quarter 2024 Financial Results
Conference Call and Webcast Scheduled for Wednesday, May 29th at 8:30 am Eastern Time 
From MediWound Ltd.
Via GlobeNewswire
MediWound to Present New Data from EscharEx® Phase II Studies at Three Leading Wound Care Conferences
From MediWound Ltd.
Via GlobeNewswire
MediWound Ltd. (NASDAQ: MDWD) Sets New 52-Week High in Wednesday Session
Via Investor Brand Network
MDWD Stock Earnings: MediWound Beats EPS, Beats Revenue for Q4 2023
MDWD stock results show that MediWound beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace
MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
From MediWound Ltd.
Via GlobeNewswire
Earnings Scheduled For March 21, 2024
Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is expected to report quarterly earnings at $0.02 per share on revenue of $16.47 million. 
Via Benzinga
MediWound to Report Fourth Quarter and Full Year 2023 Financial Results
Conference Call and Webcast Scheduled for Thursday, March 21st at 8:30 am Eastern Time 
From MediWound Ltd.
Via GlobeNewswire
MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled Study
Results demonstrate superiority of EscharEx®, a bromelain-based gel vs. SANTYL®, a collagenase ointment, in wound debridement, promotion of granulation tissue, and time to wound closure in patients... 
From MediWound Ltd.
Via GlobeNewswire
MediWound to Participate in Two Upcoming Investor Conferences
From MediWound Ltd.
Via GlobeNewswire
MediWound Announces that FDA has Accepted for Review the Supplement to the NexoBrid BLA to Include Pediatric Patients with Severe Thermal Burns
From MediWound Ltd.
Via GlobeNewswire
Innovative Burn Care: MediWound Bags Additional DoD Grant For NexoBrid Development
Biopharmaceutical company MediWound Ltd (NASDAQ: MDWD) reported that the U.S. 
Via Benzinga
MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid® Development for the U.S. Army
Awarded additional $6.7 million to advance NexoBrid as a non-surgical field care solution; R&D project budget increased to $14.4 million 
From MediWound Ltd.
Via GlobeNewswire
MediWound Announces Peer-Reviewed Publication of EscharEx® Mechanism of Action Study Assessing Its Effects on Biofilm and Microbial Loads
Results show EscharEx to be safe and effective, and suggest it can go beyond traditional expectations for enzymatic debridement 
From MediWound Ltd.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback